Equities analysts expect that Codexis, Inc. (NASDAQ:CDXS) will post $0.02 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Codexis’ earnings. Codexis also posted earnings per share of $0.02 in the same quarter last year. The company is expected to issue its next quarterly earnings results on Thursday, March 14th.
According to Zacks, analysts expect that Codexis will report full-year earnings of ($0.06) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.09) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Codexis.
Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.03. The firm had revenue of $16.95 million for the quarter, compared to the consensus estimate of $14.63 million. Codexis had a negative return on equity of 25.72% and a negative net margin of 14.26%.
Several equities research analysts have recently issued reports on CDXS shares. BidaskClub raised Codexis from a “buy” rating to a “strong-buy” rating in a report on Friday, November 23rd. HC Wainwright set a $17.00 price objective on Codexis and gave the stock a “buy” rating in a research note on Monday, November 12th. Zacks Investment Research lowered Codexis from a “strong-buy” rating to a “hold” rating in a report on Monday, October 15th. Finally, Craig Hallum boosted their price target on Codexis from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, September 5th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.40.
In related news, Director Bernard J. Kelley sold 10,207 shares of Codexis stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $18.12, for a total value of $184,950.84. Following the completion of the sale, the director now owns 215,461 shares in the company, valued at approximately $3,904,153.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathleen Sereda Glaub sold 14,492 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $18.83, for a total transaction of $272,884.36. Following the completion of the transaction, the director now directly owns 63,534 shares of the company’s stock, valued at approximately $1,196,345.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 273,152 shares of company stock worth $4,799,311. 11.40% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of CDXS. BlackRock Inc. boosted its holdings in Codexis by 27.3% during the second quarter. BlackRock Inc. now owns 3,402,575 shares of the biotechnology company’s stock worth $48,996,000 after buying an additional 729,552 shares in the last quarter. FMR LLC purchased a new stake in shares of Codexis in the second quarter valued at about $7,452,000. Wells Fargo & Company MN lifted its holdings in shares of Codexis by 35.8% in the third quarter. Wells Fargo & Company MN now owns 1,826,947 shares of the biotechnology company’s stock valued at $31,332,000 after purchasing an additional 481,273 shares in the last quarter. Castleark Management LLC purchased a new stake in shares of Codexis in the second quarter valued at about $6,239,000. Finally, Sensato Investors LLC purchased a new stake in shares of Codexis in the third quarter valued at about $3,645,000. Institutional investors and hedge funds own 80.33% of the company’s stock.
NASDAQ CDXS traded down $1.04 on Friday, hitting $21.21. 490,894 shares of the company traded hands, compared to its average volume of 351,637. The company has a market capitalization of $1.15 billion, a PE ratio of -42.42 and a beta of -1.45. Codexis has a 52-week low of $6.75 and a 52-week high of $23.05.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Further Reading: What Does Beta Mean In Stock Selection
Get a free copy of the Zacks research report on Codexis (CDXS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.